Nasdaq clarifies bases for KaloBios delisting

• In a letter to KaloBios Pharmaceuticals (KBIO), Nasdaq notifies the company that its Chapter 11 bankruptcy filing is a separate and additional basis for delisting, as is the resignation of two board members, Tom Fernandez and Marek Biestek, which leaves only one member on its audit committee.
• The company's delisting appeal and the additional bases will be discussed at the hearing on February 25.
• Previously: KaloBios files delisting appeal, hearing set for February 25 (Dec. 29)